Security record · archived quarter
PRGO
Perrigo Company plc · Healthcare · Drug Manufacturers - Specialty & Generic
2Tracked holders
+1Δ holders
170.32KShares held
$2.41MReported value
+1New positions
−0Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | +1 | 170.32K | $2.41M | +1 | n/a |
| Q2 2026 | 100 | +3 | 113.08M | $1.17B | +10 | −8 |
| Q1 2026 | 101 | +4 | 101.94M | $1.09B | +11 | −8 |
| Q4 2025 | 98 | -2 | 106.62M | $1.48B | +3 | −4 |
| Q3 2025 | 19 | 0 | 63.63M | $1.42B | +1 | −2 |
| Q2 2025 | 17 | 0 | 58.29M | $1.56B | n/a | n/a |
| Q1 2025 | 14 | +1 | 29.73M | $833.59M | +1 | n/a |
| Q4 2024 | 13 | -2 | 24.99M | $642.39M | n/a | −2 |
| Q3 2024 | 14 | -1 | 13.07M | $342.69M | n/a | −1 |
| Q2 2024 | 15 | n/a | 10.85M | $278.70M | n/a | n/a |
Who holds it · Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | TD Waterhouse Canada Inc. | 116.17K | New | $1.62M | 0.0% | New | 1 | SEC ↗ |
| 2 | Wealth Enhancement Advisory… | 54.15K | -29.7% | $785,219 | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| TD Waterhouse Canada Inc. | $1.62M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 326 holders, 151.12M shares, $1.41B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Sep 08
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
Aug 14
SC 13G/A: PRICE T ROWE ASSOCIATES INC /MD/
Jul 29
SC 13G/A: BlackRock, Inc.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2026 ·
Methodology ·
Get this via the API